Chlorine in PDB 2vip: Fragment-Based Discovery of Mexiletine Derivatives As Orally Bioavailable Inhibitors of Urokinase-Type Plasminogen Activator
Enzymatic activity of Fragment-Based Discovery of Mexiletine Derivatives As Orally Bioavailable Inhibitors of Urokinase-Type Plasminogen Activator
All present enzymatic activity of Fragment-Based Discovery of Mexiletine Derivatives As Orally Bioavailable Inhibitors of Urokinase-Type Plasminogen Activator:
3.4.21.73;
Protein crystallography data
The structure of Fragment-Based Discovery of Mexiletine Derivatives As Orally Bioavailable Inhibitors of Urokinase-Type Plasminogen Activator, PDB code: 2vip
was solved by
M.Frederickson,
O.Callaghan,
G.Chessari,
M.Congreve,
S.R.Cowan,
J.E.Matthews,
R.Mcmenamin,
D.Smith,
M.Vinkovic,
N.G.Wallis,
with X-Ray Crystallography technique. A brief refinement statistics is given in the table below:
Resolution Low / High (Å)
|
27.62 /
1.72
|
Space group
|
P 21 21 21
|
Cell size a, b, c (Å), α, β, γ (°)
|
52.488,
54.382,
81.029,
90.00,
90.00,
90.00
|
R / Rfree (%)
|
16.2 /
23.8
|
Chlorine Binding Sites:
The binding sites of Chlorine atom in the Fragment-Based Discovery of Mexiletine Derivatives As Orally Bioavailable Inhibitors of Urokinase-Type Plasminogen Activator
(pdb code 2vip). This binding sites where shown within
5.0 Angstroms radius around Chlorine atom.
In total 4 binding sites of Chlorine where determined in the
Fragment-Based Discovery of Mexiletine Derivatives As Orally Bioavailable Inhibitors of Urokinase-Type Plasminogen Activator, PDB code: 2vip:
Jump to Chlorine binding site number:
1;
2;
3;
4;
Chlorine binding site 1 out
of 4 in 2vip
Go back to
Chlorine Binding Sites List in 2vip
Chlorine binding site 1 out
of 4 in the Fragment-Based Discovery of Mexiletine Derivatives As Orally Bioavailable Inhibitors of Urokinase-Type Plasminogen Activator
Mono view
Stereo pair view
|
A full contact list of Chlorine with other atoms in the Cl binding
site number 1 of Fragment-Based Discovery of Mexiletine Derivatives As Orally Bioavailable Inhibitors of Urokinase-Type Plasminogen Activator within 5.0Å range:
probe
|
atom
|
residue
|
distance (Å)
|
B
|
Occ
|
A:Cl1247
b:15.3
occ:0.50
|
CL1
|
A:L1R1247
|
0.0
|
15.3
|
0.5
|
CL1
|
A:L1R1247
|
0.5
|
22.5
|
0.5
|
C15
|
A:L1R1247
|
1.7
|
8.7
|
0.5
|
C15
|
A:L1R1247
|
1.8
|
22.2
|
0.5
|
C14
|
A:L1R1247
|
2.7
|
24.2
|
0.5
|
C14
|
A:L1R1247
|
2.7
|
9.8
|
0.5
|
C17
|
A:L1R1247
|
2.7
|
12.6
|
0.5
|
C17
|
A:L1R1247
|
2.8
|
21.6
|
0.5
|
O18
|
A:L1R1247
|
3.1
|
12.6
|
0.5
|
O18
|
A:L1R1247
|
3.1
|
17.3
|
0.5
|
O
|
A:HOH2266
|
3.2
|
38.1
|
1.0
|
SG
|
A:CYS220
|
3.3
|
14.6
|
1.0
|
N
|
A:GLN192
|
3.3
|
12.2
|
1.0
|
O
|
A:HOH2335
|
3.7
|
25.2
|
1.0
|
CB
|
A:GLN192
|
3.8
|
12.9
|
1.0
|
C19
|
A:L1R1247
|
3.8
|
18.6
|
0.5
|
CA
|
A:GLN192
|
3.9
|
11.5
|
1.0
|
C19
|
A:L1R1247
|
3.9
|
18.0
|
0.5
|
SG
|
A:CYS191
|
3.9
|
15.1
|
1.0
|
C13
|
A:L1R1247
|
4.0
|
23.5
|
0.5
|
C13
|
A:L1R1247
|
4.0
|
8.8
|
0.5
|
C22
|
A:L1R1247
|
4.0
|
14.9
|
0.5
|
C22
|
A:L1R1247
|
4.1
|
22.1
|
0.5
|
O
|
A:HOH2334
|
4.1
|
44.6
|
1.0
|
C
|
A:CYS191
|
4.2
|
15.2
|
1.0
|
O
|
A:GLY219
|
4.3
|
12.9
|
1.0
|
CA
|
A:CYS191
|
4.4
|
10.2
|
1.0
|
C24
|
A:L1R1247
|
4.5
|
22.4
|
0.5
|
C24
|
A:L1R1247
|
4.5
|
6.1
|
0.5
|
C
|
A:GLY219
|
4.6
|
15.9
|
1.0
|
O
|
A:HOH2349
|
4.7
|
38.9
|
1.0
|
CG
|
A:GLN192
|
4.8
|
17.9
|
1.0
|
CB
|
A:CYS191
|
4.9
|
10.3
|
1.0
|
CA
|
A:GLY219
|
4.9
|
11.9
|
1.0
|
N21
|
A:L1R1247
|
5.0
|
10.4
|
0.5
|
|
Chlorine binding site 2 out
of 4 in 2vip
Go back to
Chlorine Binding Sites List in 2vip
Chlorine binding site 2 out
of 4 in the Fragment-Based Discovery of Mexiletine Derivatives As Orally Bioavailable Inhibitors of Urokinase-Type Plasminogen Activator
Mono view
Stereo pair view
|
A full contact list of Chlorine with other atoms in the Cl binding
site number 2 of Fragment-Based Discovery of Mexiletine Derivatives As Orally Bioavailable Inhibitors of Urokinase-Type Plasminogen Activator within 5.0Å range:
probe
|
atom
|
residue
|
distance (Å)
|
B
|
Occ
|
A:Cl1247
b:22.5
occ:0.50
|
CL1
|
A:L1R1247
|
0.0
|
22.5
|
0.5
|
CL1
|
A:L1R1247
|
0.5
|
15.3
|
0.5
|
C15
|
A:L1R1247
|
1.7
|
22.2
|
0.5
|
C15
|
A:L1R1247
|
1.8
|
8.7
|
0.5
|
C17
|
A:L1R1247
|
2.7
|
12.6
|
0.5
|
C14
|
A:L1R1247
|
2.7
|
24.2
|
0.5
|
C17
|
A:L1R1247
|
2.7
|
21.6
|
0.5
|
C14
|
A:L1R1247
|
2.8
|
9.8
|
0.5
|
O18
|
A:L1R1247
|
2.9
|
12.6
|
0.5
|
O18
|
A:L1R1247
|
3.0
|
17.3
|
0.5
|
O
|
A:HOH2266
|
3.3
|
38.1
|
1.0
|
SG
|
A:CYS220
|
3.4
|
14.6
|
1.0
|
C19
|
A:L1R1247
|
3.5
|
18.6
|
0.5
|
C19
|
A:L1R1247
|
3.6
|
18.0
|
0.5
|
N
|
A:GLN192
|
3.7
|
12.2
|
1.0
|
O
|
A:GLY219
|
4.0
|
12.9
|
1.0
|
C22
|
A:L1R1247
|
4.0
|
14.9
|
0.5
|
C13
|
A:L1R1247
|
4.0
|
23.5
|
0.5
|
C22
|
A:L1R1247
|
4.0
|
22.1
|
0.5
|
C13
|
A:L1R1247
|
4.1
|
8.8
|
0.5
|
O
|
A:HOH2335
|
4.1
|
25.2
|
1.0
|
O
|
A:HOH2349
|
4.2
|
38.9
|
1.0
|
CB
|
A:GLN192
|
4.3
|
12.9
|
1.0
|
O
|
A:HOH2334
|
4.3
|
44.6
|
1.0
|
SG
|
A:CYS191
|
4.3
|
15.1
|
1.0
|
C
|
A:GLY219
|
4.3
|
15.9
|
1.0
|
CA
|
A:GLN192
|
4.3
|
11.5
|
1.0
|
C24
|
A:L1R1247
|
4.5
|
6.1
|
0.5
|
C24
|
A:L1R1247
|
4.5
|
22.4
|
0.5
|
C
|
A:CYS191
|
4.5
|
15.2
|
1.0
|
CA
|
A:GLY219
|
4.6
|
11.9
|
1.0
|
CA
|
A:CYS191
|
4.6
|
10.2
|
1.0
|
N
|
A:GLY219
|
4.7
|
12.9
|
1.0
|
N21
|
A:L1R1247
|
4.7
|
10.4
|
0.5
|
C20
|
A:L1R1247
|
4.8
|
16.1
|
0.5
|
C20
|
A:L1R1247
|
4.8
|
17.6
|
0.5
|
O
|
A:HOH2347
|
4.9
|
21.6
|
1.0
|
N
|
A:CYS220
|
5.0
|
12.6
|
1.0
|
|
Chlorine binding site 3 out
of 4 in 2vip
Go back to
Chlorine Binding Sites List in 2vip
Chlorine binding site 3 out
of 4 in the Fragment-Based Discovery of Mexiletine Derivatives As Orally Bioavailable Inhibitors of Urokinase-Type Plasminogen Activator
Mono view
Stereo pair view
|
A full contact list of Chlorine with other atoms in the Cl binding
site number 3 of Fragment-Based Discovery of Mexiletine Derivatives As Orally Bioavailable Inhibitors of Urokinase-Type Plasminogen Activator within 5.0Å range:
probe
|
atom
|
residue
|
distance (Å)
|
B
|
Occ
|
A:Cl1247
b:17.6
occ:0.50
|
CL2
|
A:L1R1247
|
0.0
|
17.6
|
0.5
|
CL2
|
A:L1R1247
|
0.5
|
17.6
|
0.5
|
C22
|
A:L1R1247
|
1.7
|
22.1
|
0.5
|
C22
|
A:L1R1247
|
1.7
|
14.9
|
0.5
|
C17
|
A:L1R1247
|
2.6
|
21.6
|
0.5
|
C17
|
A:L1R1247
|
2.7
|
12.6
|
0.5
|
C24
|
A:L1R1247
|
2.7
|
6.1
|
0.5
|
C24
|
A:L1R1247
|
2.7
|
22.4
|
0.5
|
O18
|
A:L1R1247
|
2.9
|
17.3
|
0.5
|
O18
|
A:L1R1247
|
2.9
|
12.6
|
0.5
|
C19
|
A:L1R1247
|
3.1
|
18.0
|
0.5
|
C19
|
A:L1R1247
|
3.4
|
18.6
|
0.5
|
CG1
|
A:VAL213
|
3.6
|
8.9
|
1.0
|
N
|
A:TRP215
|
3.6
|
11.8
|
1.0
|
CA
|
A:TRP215
|
3.6
|
12.3
|
1.0
|
OG
|
A:SER195
|
3.7
|
12.4
|
1.0
|
C
|
A:SER214
|
3.7
|
13.7
|
1.0
|
O
|
A:SER214
|
3.7
|
12.4
|
1.0
|
C20
|
A:L1R1247
|
3.7
|
16.1
|
0.5
|
C20
|
A:L1R1247
|
3.8
|
17.6
|
0.5
|
O
|
A:HOH2331
|
3.9
|
19.1
|
1.0
|
C
|
A:TRP215
|
3.9
|
14.3
|
1.0
|
C15
|
A:L1R1247
|
3.9
|
22.2
|
0.5
|
C13
|
A:L1R1247
|
4.0
|
23.5
|
0.5
|
C13
|
A:L1R1247
|
4.0
|
8.8
|
0.5
|
C15
|
A:L1R1247
|
4.0
|
8.7
|
0.5
|
O
|
A:TRP215
|
4.0
|
10.9
|
1.0
|
N
|
A:SER214
|
4.4
|
9.9
|
1.0
|
OG
|
A:SER190
|
4.4
|
16.2
|
1.0
|
C14
|
A:L1R1247
|
4.5
|
24.2
|
0.5
|
C14
|
A:L1R1247
|
4.5
|
9.8
|
0.5
|
O
|
A:HOH2191
|
4.5
|
16.8
|
1.0
|
CA
|
A:SER214
|
4.6
|
9.0
|
1.0
|
N
|
A:GLY216
|
4.6
|
11.1
|
1.0
|
O
|
A:CYS191
|
4.6
|
13.2
|
1.0
|
O
|
A:HOH2347
|
4.6
|
21.6
|
1.0
|
C
|
A:VAL213
|
4.9
|
10.7
|
1.0
|
CB
|
A:SER195
|
4.9
|
7.6
|
1.0
|
N
|
A:SER195
|
4.9
|
9.8
|
1.0
|
CA
|
A:SER195
|
5.0
|
9.6
|
1.0
|
C
|
A:CYS191
|
5.0
|
15.2
|
1.0
|
N21
|
A:L1R1247
|
5.0
|
14.9
|
0.5
|
|
Chlorine binding site 4 out
of 4 in 2vip
Go back to
Chlorine Binding Sites List in 2vip
Chlorine binding site 4 out
of 4 in the Fragment-Based Discovery of Mexiletine Derivatives As Orally Bioavailable Inhibitors of Urokinase-Type Plasminogen Activator
Mono view
Stereo pair view
|
A full contact list of Chlorine with other atoms in the Cl binding
site number 4 of Fragment-Based Discovery of Mexiletine Derivatives As Orally Bioavailable Inhibitors of Urokinase-Type Plasminogen Activator within 5.0Å range:
probe
|
atom
|
residue
|
distance (Å)
|
B
|
Occ
|
A:Cl1247
b:17.6
occ:0.50
|
CL2
|
A:L1R1247
|
0.0
|
17.6
|
0.5
|
CL2
|
A:L1R1247
|
0.5
|
17.6
|
0.5
|
C22
|
A:L1R1247
|
1.7
|
22.1
|
0.5
|
C22
|
A:L1R1247
|
1.8
|
14.9
|
0.5
|
C24
|
A:L1R1247
|
2.7
|
22.4
|
0.5
|
C17
|
A:L1R1247
|
2.7
|
21.6
|
0.5
|
C24
|
A:L1R1247
|
2.7
|
6.1
|
0.5
|
C17
|
A:L1R1247
|
2.8
|
12.6
|
0.5
|
O18
|
A:L1R1247
|
2.9
|
17.3
|
0.5
|
O18
|
A:L1R1247
|
3.0
|
12.6
|
0.5
|
CG1
|
A:VAL213
|
3.3
|
8.9
|
1.0
|
C19
|
A:L1R1247
|
3.3
|
18.0
|
0.5
|
OG
|
A:SER195
|
3.4
|
12.4
|
1.0
|
C19
|
A:L1R1247
|
3.6
|
18.6
|
0.5
|
C20
|
A:L1R1247
|
3.9
|
16.1
|
0.5
|
C
|
A:SER214
|
3.9
|
13.7
|
1.0
|
N
|
A:TRP215
|
3.9
|
11.8
|
1.0
|
O
|
A:SER214
|
4.0
|
12.4
|
1.0
|
C20
|
A:L1R1247
|
4.0
|
17.6
|
0.5
|
C13
|
A:L1R1247
|
4.0
|
23.5
|
0.5
|
O
|
A:HOH2331
|
4.0
|
19.1
|
1.0
|
C15
|
A:L1R1247
|
4.0
|
22.2
|
0.5
|
C13
|
A:L1R1247
|
4.0
|
8.8
|
0.5
|
C15
|
A:L1R1247
|
4.1
|
8.7
|
0.5
|
CA
|
A:TRP215
|
4.1
|
12.3
|
1.0
|
O
|
A:CYS191
|
4.2
|
13.2
|
1.0
|
OG
|
A:SER190
|
4.3
|
16.2
|
1.0
|
C
|
A:TRP215
|
4.4
|
14.3
|
1.0
|
N
|
A:SER214
|
4.4
|
9.9
|
1.0
|
O
|
A:TRP215
|
4.4
|
10.9
|
1.0
|
N
|
A:SER195
|
4.5
|
9.8
|
1.0
|
C14
|
A:L1R1247
|
4.5
|
24.2
|
0.5
|
C14
|
A:L1R1247
|
4.5
|
9.8
|
0.5
|
CB
|
A:SER195
|
4.6
|
7.6
|
1.0
|
CA
|
A:SER195
|
4.6
|
9.6
|
1.0
|
C
|
A:CYS191
|
4.7
|
15.2
|
1.0
|
CA
|
A:SER214
|
4.7
|
9.0
|
1.0
|
CB
|
A:VAL213
|
4.8
|
11.9
|
1.0
|
O
|
A:HOH2191
|
4.8
|
16.8
|
1.0
|
C
|
A:VAL213
|
4.8
|
10.7
|
1.0
|
CB
|
A:SER190
|
4.8
|
11.1
|
1.0
|
O
|
A:ACT1245
|
4.8
|
13.9
|
1.0
|
O
|
A:HOH2347
|
5.0
|
21.6
|
1.0
|
|
Reference:
M.Frederickson,
O.Callaghan,
G.Chessari,
M.Congreve,
S.R.Cowan,
J.E.Matthews,
R.Mcmenamin,
D.Smith,
M.Vinkovic,
N.G.Wallis.
Fragment-Based Discovery of Mexiletine Derivatives As Orally Bioavailable Inhibitors of Urokinase-Type Plasminogen Activator J.Med.Chem. V. 51 183 2008.
ISSN: ISSN 0022-2623
PubMed: 18163548
DOI: 10.1021/JM701359Z
Page generated: Sat Jul 20 11:53:01 2024
|